Tempest turns to Factor for lifeline, trading majority stake for CAR-Ts and CEO
After laying off 80% of staffers this spring, Tempest Therapeutics is acquiring several CAR-T programs from Factor Bioscience and bringing the latter’s CEO on board to helm the company. The…